Evaluation of Effectiveness of the 23-Valent Pneumococcal Capsular Polysaccharide Vaccine for HIV-Infected Patients | Allergy and Clinical Immunology | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.204.227.34. Please contact the publisher to request reinstatement.
1.
Redd  SCRutherford  GWSande  MA  et al.  The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents.  J Infect Dis. 1990;1621012- 1017Google ScholarCrossref
2.
Janoff  ENBreiman  RFDaley  CLHopewell  PC Pneumococcal disease during HIV infection: epidemiologic, clinical, and immunologic perspectives.  Ann Intern Med. 1992;117314- 324Google ScholarCrossref
3.
Keller  DWBreiman  RF Preventing bacterial respiratory tract infections among persons infected with human immunodeficiency virus.  Clin Infect Dis. 1995;21(suppl 1)S77- S83Google ScholarCrossref
4.
Shapiro  EDBerg  ATAustrian  R  et al.  The protective efficacy of polyvalent pneumococcal polysaccharide vaccine.  N Engl J Med. 1991;3251453- 1460Google ScholarCrossref
5.
Butler  JCBreiman  RFCampbell  JFLipman  HBBroome  CVFacklam  RR Pneumococcal polysaccharide vaccine efficacy: an evaluation of current recommendations.  JAMA. 1993;2701826- 1831Google ScholarCrossref
6.
Centers for Disease Control and Prevention, Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP).  MMWR Morb Mortal Wkly Rep. 1997;46 ((RR-8)) 1- 24Google Scholar
7.
American College of Physicians, Guide for Adult Immunization.  Philadelphia, Pa American College of Physicians1994;112
8.
Centers for Disease Control and Prevention, 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus.  Atlanta, Ga USPHS/IDSA Prevention of Opportunistic Infections Working Group1997;46 ((RR-12)) 1- 46
9.
Lifson  ARRutherford  GWJaffe  HW The natural history of human immunodeficiency virus infection.  J Infect Dis. 1988;1581360- 1367Google ScholarCrossref
10.
Facklam  RRWashington  JA  II Streptococcus and related catalase-negative gram positive cocci. Balows  AHausler  WJHermann  RLIsenberg  HDShadomy  HJeds. Manual of Clinical Microbiology 5th ed. Washington, DC American Society for Microbiology1991;238- 257Google Scholar
11.
Smith  PGRodrigues  LCFine  PE Assessment of the protective efficacy of vaccines against common diseases using case-control and cohort studies.  Int J Epidemiol. 1984;1387- 93Google ScholarCrossref
12.
SAS Institute Inc, SAS/STAT Software: Changes and Enhancements Through Release 6.11.  Cary, NC SAS Institute Inc1996;
13.
Brichacek  BSwindells  SJanoff  ENPirruccello  SStevenson  M Increased plasma human immunodeficiency virus type 1 burden following antigenic challenge with pneumococcal vaccine.  J Infect Dis. 1996;1741191- 1199Google ScholarCrossref
14.
Gebo  KAMoore  RDKeruly  JCChaisson  RE Risk factors for pneumococcal disease in human immunodeficiency virus–infected patients.  J Infect Dis. 1996;173857- 862Google ScholarCrossref
15.
French  NNakiyingi  JCarpenter  LM  et al.  23-Valent pneumococcal polysaccharide vaccine in HIV-1-infected Ugandan adults: double-blind, randomised and placebo controlled trial.  Lancet. 2000;3552106- 2111Google ScholarCrossref
16.
Jones  JLHanson  DLDworkin  MS  et al.  Surveillance for AIDS-defining opportunistic illnesses, 1992-1997.  MMWR Morb Mortal Wkly Rep. 1999;48 ((SS-2)) 1- 22Google Scholar
17.
Ward  JWHanson  DLJones  JL Pneumococcal vaccination and the incidence of pneumonia among HIV-infected persons.  Paper presented at: Infectious Disease Society of America National Meeting September 1996 New Orleans, La.
18.
Farr  BMJohnston  BLCobb  DK  et al.  Preventing pneumococcal bacteremia in patients at risk: results of a matched case-control study.  Arch Intern Med. 1995;1552336- 2340Google ScholarCrossref
19.
Sims  RVSteinmann  WCMcConville  JHKing  LRZwick  WCSchwartz  JS The clinical effectiveness of pneumococcal vaccine in the elderly.  Ann Intern Med. 1988;108653- 657Google ScholarCrossref
20.
Breiman  RFSpika  JSNavarro  VCDarden  PMDarby  CP Pneumococcal bacteremia in Charleston County: a decade later.  Arch Intern Med. 1990;1501401- 1405Google ScholarCrossref
21.
Straus  WLPlouffe  JFFile  TF  et al.  Risk factors for domestic acquisition of Legionnaires' disease.  Arch Intern Med. 1996;1561685- 1692Google ScholarCrossref
22.
Fischer  MHedberg  KCardosi  P  et al.  Tobacco smoke as a risk factor for meningococcal disease.  Pediatr Infect Dis J. 1997;16979- 983Google ScholarCrossref
23.
Hendley  JOSande  MAStewart  PMGwaltney  JM Spread of Streptococcus pneumoniae in families: carriage rates and distribution of types.  J Infect Dis. 1975;13255- 61Google ScholarCrossref
24.
Henderson  FWLilligan  PHWalt  KGoff  DA Nasopharyngeal carriage of antibiotic-resistant pneumococci by children in group day care.  J Infect Dis. 1988;157256- 263Google ScholarCrossref
25.
Nuorti  JPButler  JCFarley  MM  et al.  Cigarette smoking and invasive pneumococcal disease: Active Bacterial Core Surveillance Team.  N Engl J Med. 2000;342681- 689Google ScholarCrossref
26.
Schuchat  ABroome  CVHightower  ACosta  SJParkin  W Use of surveillance for invasive pneumococcal disease to estimate the size of the immunosuppressed HIV-infected population.  JAMA. 1991;2653275- 3279Google ScholarCrossref
27.
Chan  CYMolrine  DCGeorge  S  et al.  Pneumococcal conjugate vaccine primes for antibody responses to polysaccharide pneumococcal vaccine after treatment of Hodgkin's disease.  J Infect Dis. 1996;173256- 258Google ScholarCrossref
Original Investigation
September 25, 2000

Evaluation of Effectiveness of the 23-Valent Pneumococcal Capsular Polysaccharide Vaccine for HIV-Infected Patients

Author Affiliations

From the National Center for Infectious Diseases, Centers for Disease Control and Prevention (Drs Breiman, Keller, Phelan, Sniadack, and Schuchat), and Emory University School of Medicine and Veterans Administration Medical Center (Drs Stephens, Rimland, and Farley), Atlanta, Ga; and School of Public Health, University of California, Berkeley (Dr Reingold).

Arch Intern Med. 2000;160(17):2633-2638. doi:10.1001/archinte.160.17.2633
Abstract

Background  We conducted a retrospective case-control study to evaluate effectiveness of pneumococcal vaccine against invasive disease among adults with human immunodeficiency virus (HIV) infection in San Francisco, Calif, and Atlanta, Ga.

Methods  Case patients were 18- to 55-year-old subjects with HIV infection who were admitted to selected hospitals in Atlanta or San Francisco from February 1992 to April 1995 from whom Streptococcus pneumoniae was isolated from a normally sterile site. Controls were HIV-infected patients of similar age matched to cases by hospital of admission and CD4 lymphocyte count (<0.20, 0.20-0.499, ≥0.50 × 109/L [<200, 200-499, ≥500 cells/mm3]) or clinical stage of acquired immunodeficiency syndrome. Case and control subjects were restricted to persons known to have HIV infection before hospital admission. Analysis used matched univariate and conditional logistic regression.

Results  One hundred seventy-six case patients and 327 controls were enrolled. By univariate analysis, persons with pneumococcal disease were more likely to be black, be current smokers, and have close contact with children. Adjusted for these factors and CD4 cell count, pneumococcal vaccine effectiveness was 49% (95% confidence interval [CI], 12%-70%). Adjusting for all variables and key interaction terms, vaccine effectiveness among whites was 76% (95% CI, 35%-91%), whereas effectiveness among blacks was 24% (95% CI, −50% to 61%). Among controls, vaccination was significantly less common among blacks (29% vs 45%; P<.005).

Conclusions  Pneumococcal vaccine demonstrated protection against invasive pneumococcal infections among white but not black HIV-infected adults. Failure to demonstrate effectiveness among blacks may be due to limited power because of low use of the vaccine in this population, immunization at more advanced stages of immunosuppression, or unmeasured factors. These data support current recommendations for use of pneumococcal vaccine in HIV-infected persons and highlight a clear need for strategies to improve vaccine-induced protection.

×